Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
about
Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategiesPlasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmissionIdentification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium bergheiGene-specific signatures of elevated non-synonymous substitution rates correlate poorly across the Plasmodium genus.The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coliBlocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.Challenges and approaches for mosquito targeted malaria control.Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparumPlasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunizationPlasmodium vivax malaria vaccines: why are we where we are?Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationVaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malariaIn vitro generation of Plasmodium falciparum ookinetes.Current developments in malaria transmission-blocking vaccines.Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assaysMonoclonal antibody MG96 completely blocks Plasmodium yoelii development in Anopheles stephensi.Antigenic repertoire of Plasmodium vivax transmission-blocking vaccine candidates from the Indian subcontinent.Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.Lack of molecular correlates of Plasmodium vivax ookinete development.N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.Recombinant Pvs48/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoesComparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, MyanmarDoes malaria suffer from lack of memory?Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titerEvolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive SelectionImmunological Cross-Reactivity between Malaria Vaccine Target Antigen P48/45 in Plasmodium vivax and P. falciparum and Cross-Boosting of Immune Responses.Genetic diversity of transmission-blocking vaccine candidate Pvs48/45 in Plasmodium vivax populations in China3'-RACE Amplification of Aminopeptidase N Gene from Anopheles stephensi Applicable in Transmission Blocking Vaccines.Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolatesPlasmodium vivax: who cares?Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.Human host-derived cytokines associated with Plasmodium vivax transmission from acute malaria patients to Anopheles darlingi mosquitoes in the Peruvian AmazonVarious carrier system(s)- mediated genetic vaccination strategies against malaria.Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection.What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?
P2860
Q24805493-BB5E6DEF-8A73-4466-A06E-8C23CC9268FCQ27973462-C64D2566-2621-4EB9-805D-1E21E710268AQ27974514-854FC553-08EC-40AD-BC49-3453BB3F7EABQ30043378-8327EDF6-3448-41C7-8529-19B57D426AB8Q33338427-BC39D1DB-4C3C-44EF-94AB-143B015D69F3Q33558061-EDF832AC-E944-4DC6-A530-1E968146B42BQ34008897-9D1DDFDA-562B-4EAB-ACF4-77A3F14F03F1Q34045009-5FB285CD-0725-43AE-A027-15079DBCB155Q34077952-E145C6AB-BB50-4ABA-A483-49391758290FQ34111897-A18419DB-FFCA-4799-915D-BFA5EFFB53C0Q34119427-6931BF4E-30F3-4213-B706-BEDFC7EB635FQ34170071-02E5C36D-FE7B-4F2B-8206-CD8AE8F1EFF4Q34177472-6594360D-ABE2-4059-8192-5AEB2A8B4585Q34260722-266309E1-D42B-46B7-A013-C25E25305FA1Q34341749-5BEA6054-9153-4C0B-B0E6-589D5CF92F35Q34451883-204E153A-A6D1-481A-AA9C-4CBEDEE4EF07Q34618434-F30BA0E3-B0C6-43C2-9897-646E3AACE65FQ34945115-98815F6D-C8F5-43F0-8130-854F9FF13572Q35014586-289A21C4-50E2-4459-9E8E-E0B7291E95FFQ35088997-7352EED4-1807-4BF4-8D46-6F0523653265Q35131352-F514E69B-D82D-47C0-95CE-8DF0D74FC0C0Q35138720-A8A52223-3FAD-48C0-9E9B-88FD892448B7Q35182086-AD96F106-3D37-444D-9E27-7959B792B4C1Q35186079-6F69F633-8CC3-486D-AB03-1D00E33806EAQ35884250-8794970C-0B06-45B3-9C05-F419D9EEAEA5Q35947113-7DC9A7D0-CF3C-4E0D-877C-D792AA02BF23Q35982771-250E7199-5697-426F-A4CA-FDB2DD53C267Q36062237-4FAC3C0D-125D-4B45-AA18-E49A29BA7F57Q36082968-4C6E0B56-1944-4FF7-83B3-038E4A559CCBQ36336302-821A4A8E-59B0-48F0-9FC3-6D85013B4396Q36571471-BF295A23-F91B-4B5C-ABD2-E88D08DB7FC0Q36795388-E416EF1D-9C50-4467-8490-1BFFE19A33CDQ36846823-C766BFEC-3C05-4133-B361-0BC354172E07Q37018632-D531952D-8C12-4A74-9400-77BD93F1CD4DQ37025716-2D4E7047-E90B-41F4-956E-EE551EE3F7A4Q37119561-474D12B3-D964-43A5-BB3B-9BE04900D8FEQ37150329-45B89508-F309-4873-B04B-92E1FDA6FDE8Q37160241-8ECCF066-2B59-42A7-A3A1-215DAE80D889Q37451022-CF901600-B30A-44A0-A203-0DE17F412040Q37638131-783D56F6-5F83-4F6E-ACDD-5D91BADFC4AA
P2860
Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@ast
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@en
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@nl
type
label
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@ast
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@en
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@nl
prefLabel
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@ast
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@en
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@nl
P2093
P2860
P921
P1476
Antibodies to malaria vaccine ...... um vivax to infect mosquitoes.
@en
P2093
A W Stowers
D C Kaslow
J S Sattabongkot
N Suwanabun
W E Collins
P2860
P304
P356
10.1128/IAI.68.12.6618-6623.2000
P407
P577
2000-12-01T00:00:00Z